Press release
Non-Alcoholic Steatohepatitis Market Set to Grow Substantially Through 2034, DelveInsight Projects | Inventiva Pharma, Zydus Therapeutics, Novo Nordisk A/S, Viking Therapeutics, Madrigal Pharma, Inc, Hepagene, Enyo Pharma, Galectin Therapeutics Inc., 89bi
To Know in detail about the Non-Alcoholic Steatohepatitis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Non-Alcoholic Steatohepatitis Market Forecast
https://www.delveinsight.com/sample-request/nonalcoholic-steatohepatitis-nash-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key facts of the Non-Alcoholic Steatohepatitis Market Report:
• Among the 7MM countries Non-Alcoholic Steatohepatitis market size was valued approximately USD 2,114 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
• In May 2025, An interim analysis from the Phase III ESSENCE trial (NCT04822181), published in The New England Journal of Medicine, showed that weekly semaglutide led to notable improvements in both steatohepatitis and fibrosis among patients with metabolic dysfunction-associated steatohepatitis (MASH). The treatment also improved metabolic indicators and noninvasive liver health markers. Researchers emphasized semaglutide's ability to target both liver damage and the metabolic dysfunction driving disease progression, highlighting its promise as a holistic treatment option for MASH.
• In March 2025, Long-term use of Rezdiffra (resmetirom) has demonstrated a reduction in liver fibrosis in most patients with compensated cirrhosis due to metabolic dysfunction-associated steatohepatitis (MASH), where the liver continues to function despite permanent scarring. These results come from two-year data of the Phase 3 MAESTRO-NAFLD-1 trial (NCT04197479), recently announced by the drug's developer, Madrigal Pharmaceuticals.
• In 2023, the United States held the largest NASH market size among the 7MM, valued at around USD 1,519 million, with projections indicating further growth by 2034.
• In 2023, Germany had the highest Nonalcoholic Steatohepatitis (NASH) market size among European countries, reaching USD 89 million, whereas Spain recorded the lowest, with a market size of USD 50 million.
• Japan's Nonalcoholic Steatohepatitis (NASH) market size was approximately USD 260 million in 2023 and is projected to grow further by 2034.
• In 2023, the United States had the largest NASH market size among the 7MM, estimated at around USD 1,519 million, with further growth expected by 2034.
• In 2023, the estimated prevalence of NASH in the 7MM was around 42 million cases. Of these, approximately 15 million were diagnosed, and this figure is expected to rise by 2034 across the 7MM.
• Nonalcoholic Steatohepatitis severity-specific prevalence is categorized into F0, F1, F2, F3, and F4 stages. In the United States, the F1 stage accounted for the largest proportion of diagnosed cases in 2023, representing approximately 38% of the total.
• According to DelveInsight's estimates, the United States recorded the highest number of diagnosed prevalent cases of Nonalcoholic Steatohepatitis in 2023, totaling around 9.4 million. In comparison, the EU4 and the UK reported approximately 3.6 million cases, while Japan accounted for about 2.5 million cases.
• Based on gender classification, the diagnosed prevalent cases of Nonalcoholic Steatohepatitis were higher in males than females across the 7MM, with males comprising 56% of the total cases.
• In 2023, Japan represented about 16% of the total diagnosed prevalent NASH cases within the 7MM, and this number is anticipated to rise throughout the study period (2020-2034).
• Key Non-Alcoholic Steatohepatitis Companies: Inventiva Pharma, Zydus Therapeutics, Novo Nordisk A/S, Viking Therapeutics, Madrigal Pharmaceuticals, Inc, Hepagene, Enyo Pharma, Galectin Therapeutics Inc., 89bio, Inc., Akero Therapeutics, Inc, NeuroBo Pharmaceuticals Inc, Novo Nordisk A/S, J2H Biotech, Haisco Pharmaceutical, Altimmune, Inc., AstraZeneca, Boehringer Ingelheim, Can-Fite BioPharma, Madrigal Pharmaceuticals, GlaxoSmithKline, 89bio, Inc., Akero Therapeutics, Inc, Regeneron Pharmaceuticals, Hepagene (Shanghai) Co., Ltd., Inventiva Pharma, Hanmi Pharmaceutical, Madrigal Pharmaceuticals, Inc., Sinew Pharma Inc., Boston Pharmaceuticals, and others
• Key Non-Alcoholic Steatohepatitis Therapies: Lanifibranor, Saroglitazar Magnesium, Semaglutide, VK2809, MGL-3196, HPG1860, Vonafexor (EYP001), Belapectin, Pegozafermin, Efruxifermin (EFX), DA-1241, NNC0194, J2H-1702, HSK31679, Pemvidutide, AZD9550, Survodutide, Namodenoson, Resmetirom, GSK4532990, BIO89-100, EFX, ALN-HSD, HPG1860, IVA337, HM15211, MGL-3196, SNP-610, BOS-580, and others
• The Non-Alcoholic Steatohepatitis epidemiology based on gender analyzed that males have a slightly higher likelihood of being affected by NASH compared to females in the 7MM.
• The Non-Alcoholic Steatohepatitis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Non-Alcoholic Steatohepatitis pipeline products will significantly revolutionize the Non-Alcoholic Steatohepatitis market dynamics.
Non-Alcoholic Steatohepatitis Overview
Non-Alcoholic Steatohepatitis (NASH) is a liver condition characterized by the accumulation of fat in the liver, inflammation, and liver cell damage, resembling alcoholic liver disease but occurring in individuals who consume little to no alcohol. NASH is considered a severe form of non-alcoholic fatty liver disease (NAFLD) and can lead to complications such as cirrhosis, liver failure, and hepatocellular carcinoma (liver cancer).
Get a Free sample for the Non-Alcoholic Steatohepatitis Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/nonalcoholic-steatohepatitis-nash-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Non-Alcoholic Steatohepatitis Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Non-Alcoholic Steatohepatitis Epidemiology Segmentation:
The Non-Alcoholic Steatohepatitis market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Non-Alcoholic Steatohepatitis
• Prevalent Cases of Non-Alcoholic Steatohepatitis by severity
• Gender-specific Prevalence of Non-Alcoholic Steatohepatitis
• Diagnosed Cases of Episodic and Chronic Non-Alcoholic Steatohepatitis
Download the report to understand which factors are driving Non-Alcoholic Steatohepatitis epidemiology trends @ Non-Alcoholic Steatohepatitis Epidemiology Forecast
https://www.delveinsight.com/sample-request/nonalcoholic-steatohepatitis-nash-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Non-Alcoholic Steatohepatitis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Non-Alcoholic Steatohepatitis market or expected to get launched during the study period. The analysis covers Non-Alcoholic Steatohepatitis market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Non-Alcoholic Steatohepatitis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Non-Alcoholic Steatohepatitis Therapies and Key Companies
• REZDIFFRA (resmetirom): Madrigal Pharmaceuticals
• Pegozafermin: 89bio, Inc
• Efruxifermin (EFX): Akero Therapeutics, Inc.
• Belapectin: Galectin Therapeutics
• Lanifibranor: Inventiva Pharma
• Saroglitazar Magnesium: Zydus Therapeutics
• Semaglutide: Novo Nordisk A/S
• VK2809: Viking Therapeutics
• MGL-3196: Madrigal Pharmaceuticals, Inc
• HPG1860: Hepagene
• Vonafexor (EYP001): Enyo Pharma
• DA-1241: NeuroBo Pharmaceuticals Inc
• NNC0194: Novo Nordisk A/S
• J2H-1702: J2H Biotech
• HSK31679: Haisco Pharmaceutical
• Pemvidutide: Altimmune, Inc.
• AZD9550: AstraZeneca
• Survodutide: Boehringer Ingelheim
• Namodenoson: Can-Fite BioPharma
• Resmetirom: Madrigal Pharmaceuticals
• GSK4532990: GlaxoSmithKline
• BIO89-100: 89bio, Inc.
• EFX: Akero Therapeutics, Inc
• ALN-HSD: Regeneron Pharmaceuticals
• HPG1860: Hepagene (Shanghai) Co., Ltd.
• IVA337: Inventiva Pharma
• HM15211: Hanmi Pharmaceutical
• VK2809: Viking Therapeutics, Inc.
• MGL-3196: Madrigal Pharmaceuticals, Inc.
• SNP-610: Sinew Pharma Inc.
• BOS-580: Boston Pharmaceuticals
Discover more about therapies set to grab major Non-Alcoholic Steatohepatitis market share @ Non-Alcoholic Steatohepatitis Treatment Landscape
https://www.delveinsight.com/sample-request/nonalcoholic-steatohepatitis-nash-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Non-Alcoholic Steatohepatitis Market Strengths
• Growing research activities and multiple clinical trials ongoing for NASH, suggests that the number of drugs is being developed that will strengthen the market.
Non-Alcoholic Steatohepatitis Market Opportunities
• The large pool of patients suffering from NASH and lucrative opportunities for market growth create attractive prospects for key players to work in these areas
Scope of the Non-Alcoholic Steatohepatitis Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Non-Alcoholic Steatohepatitis Companies: Inventiva Pharma, Zydus Therapeutics, Novo Nordisk A/S, Viking Therapeutics, Madrigal Pharmaceuticals, Inc, Hepagene, Enyo Pharma, Galectin Therapeutics Inc., 89bio, Inc., Akero Therapeutics, Inc, NeuroBo Pharmaceuticals Inc, Novo Nordisk A/S, J2H Biotech, Haisco Pharmaceutical, Altimmune, Inc., AstraZeneca, Boehringer Ingelheim, Can-Fite BioPharma, Madrigal Pharmaceuticals, GlaxoSmithKline, 89bio, Inc., Akero Therapeutics, Inc, Regeneron Pharmaceuticals, Hepagene (Shanghai) Co., Ltd., Inventiva Pharma, Hanmi Pharmaceutical, Madrigal Pharmaceuticals, Inc., Sinew Pharma Inc., Boston Pharmaceuticals, and others
• Key Non-Alcoholic Steatohepatitis Therapies: Lanifibranor, Saroglitazar Magnesium, Semaglutide, VK2809, MGL-3196, HPG1860, Vonafexor (EYP001), Belapectin, Pegozafermin, Efruxifermin (EFX), DA-1241, NNC0194, J2H-1702, HSK31679, Pemvidutide, AZD9550, Survodutide, Namodenoson, Resmetirom, GSK4532990, BIO89-100, EFX, ALN-HSD, HPG1860, IVA337, HM15211, MGL-3196, SNP-610, BOS-580, and others
• Non-Alcoholic Steatohepatitis Therapeutic Assessment: Non-Alcoholic Steatohepatitis current marketed and Non-Alcoholic Steatohepatitis emerging therapies
• Non-Alcoholic Steatohepatitis Market Dynamics: Non-Alcoholic Steatohepatitis market drivers and Non-Alcoholic Steatohepatitis market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Non-Alcoholic Steatohepatitis Unmet Needs, KOL's views, Analyst's views, Non-Alcoholic Steatohepatitis Market Access and Reimbursement
To know more about Non-Alcoholic Steatohepatitis companies working in the treatment market, visit @ Non-Alcoholic Steatohepatitis Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/nonalcoholic-steatohepatitis-nash-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Table of Contents
1. Non-Alcoholic Steatohepatitis Market Report Introduction
2. Executive Summary for Non-Alcoholic Steatohepatitis
3. SWOT analysis of Non-Alcoholic Steatohepatitis
4. Non-Alcoholic Steatohepatitis Patient Share (%) Overview at a Glance
5. Non-Alcoholic Steatohepatitis Market Overview at a Glance
6. Non-Alcoholic Steatohepatitis Disease Background and Overview
7. Non-Alcoholic Steatohepatitis Epidemiology and Patient Population
8. Country-Specific Patient Population of Non-Alcoholic Steatohepatitis
9. Non-Alcoholic Steatohepatitis Current Treatment and Medical Practices
10. Non-Alcoholic Steatohepatitis Unmet Needs
11. Non-Alcoholic Steatohepatitis Emerging Therapies
12. Non-Alcoholic Steatohepatitis Market Outlook
13. Country-Wise Non-Alcoholic Steatohepatitis Market Analysis (2020-2034)
14. Non-Alcoholic Steatohepatitis Market Access and Reimbursement of Therapies
15. Non-Alcoholic Steatohepatitis Market Drivers
16. Non-Alcoholic Steatohepatitis Market Barriers
17. Non-Alcoholic Steatohepatitis Appendix
18. Non-Alcoholic Steatohepatitis Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Related Reports:
Non-Alcoholic Steatohepatitis Pipeline https://www.delveinsight.com/report-store/non-alcoholic-steatohepatitis-nash-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"Non-Alcoholic Steatohepatitis Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Non-Alcoholic Steatohepatitis market. A detailed picture of the Non-Alcoholic Steatohepatitis pipeline landscape is provided, which includes the disease overview and Non-Alcoholic Steatohepatitis treatment guidelines.
Non-Alcoholic Steatohepatitis Epidemiology https://www.delveinsight.com/report-store/nonalcoholic-steatohepatitis-nash-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Non-Alcoholic Steatohepatitis Epidemiology Forecast to 2034' report delivers an in-depth understanding of the disease, historical and forecasted Non-Alcoholic Steatohepatitis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports by DelveInsight
• Structural Heart Devices Market: https://www.delveinsight.com/report-store/structural-heart-devices-market-market
• Prosthetic Heart Valve Market: https://www.delveinsight.com/report-store/prosthetic-heart-valve-market
• Xerostomia Market: https://www.delveinsight.com/report-store/xerostomia-market
• Cardiac Arrythmia Market: https://www.delveinsight.com/report-store/ambulatory-arrhythmia-monitoring-devices-market
• Alopecia Market: https://www.delveinsight.com/report-store/alopecia-areata-market
• Optical Coherence Tomography Devices Market: https://www.delveinsight.com/report-store/optical-coherence-tomography-oct-devices-market
• Prediabetes Market: https://www.delveinsight.com/report-store/prediabetes-market
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
Contact No.: +14699457679
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Non-Alcoholic Steatohepatitis Market Set to Grow Substantially Through 2034, DelveInsight Projects | Inventiva Pharma, Zydus Therapeutics, Novo Nordisk A/S, Viking Therapeutics, Madrigal Pharma, Inc, Hepagene, Enyo Pharma, Galectin Therapeutics Inc., 89bi here
News-ID: 4127150 • Views: …
More Releases from DelveInsight Business Research
Global Smart Medical Devices Market to grow at a CAGR of 7.22% by 2030, Evaluate …
According to DelveInsight's analysis, The growing demand for smart medical devices is primarily driven by unhealthy diets, sedentary lifestyles, and lack of physical activity, which contribute to the rising prevalence of chronic diseases such as asthma, diabetes, hypertension, and cardiovascular disorders. Additionally, increasing awareness and adoption of internet-enabled smart medical devices in healthcare allow physicians to monitor patients' health daily and ensure proper care, boosting demand for these devices. The…
Global Platelet Aggregation Devices Market to grow at a CAGR of 7.85% by 2030, E …
According to DelveInsight's analysis, The platelet aggregation devices market is experiencing strong growth due to factors such as the increasing prevalence of cardiovascular, hematological, and other target disorders, along with the rising geriatric population worldwide. Additionally, technological advancements in platelet aggregometers-such as precise and automated platelet testing-are expected to drive demand in the coming years. The growth is further supported by increasing industry-academia collaborations, ongoing clinical studies, and a rise…
Global Occlusion Devices Market to grow at a CAGR of 6.31% by 2030, Evaluates De …
According to DelveInsight's analysis, The demand for occlusion devices is largely driven by the growing number of patients affected by various chronic conditions. Additionally, rapid technological advancements, rising preference for minimally invasive surgeries (MIS), favorable reimbursement policies for MIS, and an expanding geriatric population are key factors contributing to the overall growth of the occlusion devices market between 2024 and 2030.
DelveInsight's "Occlusion Devices Market Insights, Competitive Landscape and Market Forecast-2030"…
Hypoxia Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Hypoxia pipeline constitutes key companies continuously working towards developing Hypoxia treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Hypoxia Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Hypoxia Market.
The Hypoxia Pipeline report embraces in-depth commercial and…
More Releases for Steatohepatitis
Non-Alcoholic Steatohepatitis Treatment Market Size, Share
The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.
Non-Alcoholic Steatohepatitis Treatment Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.
The Market Size Is Expected To Reach $2.67 billion In 2028…
Non-Alcoholic Steatohepatitis (NASH) - Drug Pipeline Landscape, 2023
Nonalcoholic steatohepatitis (NASH) is a type of fatty liver disease. It is characterized by the accumulation of fat in the liver, inflammation, and damage. NASH can lead to cirrhosis, liver failure, and death. The exact cause of NASH is unknown, but it is believed to be associated with obesity, insulin resistance, and diabetes. Treatment of NASH is focused on weight loss, exercise, and the control of diabetes and insulin resistance.
NASH…
Non Alcoholic Steatohepatitis (NASH) Market Size to Hit $21,879 Million by 2028 …
According to our experience research team, Non Alcoholic Steatohepatitis (NASH) Market was valued at USD 1,569 Million in 2021, and the global Non Alcoholic Steatohepatitis (NASH) industry is projected to reach a value of USD 21,879 Million by 2028, at a CAGR of 60.4% during the forecast period 2022-2028
The report is focused on gaining various Non Alcoholic Steatohepatitis (NASH) market trends, dynamics, growth drivers, opportunities, weaknesses, strengths, and threats restraining…
Nonalcoholic Steatohepatitis Treatment Market Analysis
As per the research conducted by GME, the Global Nonalcoholic Steatohepatitis Treatment Market will grow with a CAGR value of 39.1% by 2026. Over the forecast era, the production of NASH biomarkers is expected to be aided by increasing demand for non-invasive diagnostic tools and increased patient awareness. The low use of invasive procedures for disease diagnosis is due to the high cost of liver biopsy, its invasiveness, and patients'…
Emerging Opportunities in Nonalcoholic Steatohepatitis Therapeutics Market
Global Nonalcoholic Steatohepatitis (NASH) Market: Snapshot
Nonalcoholic Steatohepatitis (NASH), a syndrome found in non-alcoholic patients, causes damage to liver that is histologically akin to alcoholic hepatitis. NASH results from fat in the liver, along with inflammation. Symptoms in NASH usually do not show, but it can be severe and lead to cirrhosis, which is permanent damage to the liver.
Those suffering from obesity, dyslipidemia, and glucose intolerance are most likely…
Global Non-alcoholic Steatohepatitis Market Research Report 2017
Report Hive Market Research Released a New Research Report of 114 pages on Title " Global Non-alcoholic Steatohepatitis Market Research Report 2017 "with detailed Analysis, Forecast and Strategies.
Non-alcoholic greasy liver malady (NAFLD) is one of the sorts of greasy liver which happens when fat is stored (steatosis) in the liver because of causes other than inordinate liquor utilize. NAFLD is the most widely recognized liver issue in created nations.
In this…
